Comprehensive review on single-cell RNA sequencing: A new frontier in Alzheimer's disease research

Jin, Wengang; Pei, JinJin; Roy, Jeane Rebecca; Jayaraman, Selvaraj; Ahalliya, Rathi Muthaiyan; Kanniappan, Gopalakrishnan Velliyur; Mironescu, Monica; Palanisamy, Chella Perumal

doi:10.1016/j.arr.2024.102454

Ageing Research Reviews

2024

DOI: 10.1016/j.arr.2024.102454

|View full text |Cite

Comprehensive review on single-cell RNA sequencing: A new frontier in Alzheimer's disease research

Wengang Jin,

JinJin Pei,

Jeane Rebecca Roy

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application

Jayaprakash,

Elumalai

2024

Chronic Diseases and Translational Medicine

View full text Add to dashboard Cite

Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD). Existing treatments, including cholinesterase inhibitors and N‐methyl D‐aspartate (NMDA) receptor antagonists, do not reverse or slow the disease course but only treat its manifestations. This limitation has brought attention to the need for treatments that modify the amyloid‐beta (Aβ) and tau pathology of the disease. One recent advancement in AD treatment is donanemab, a monoclonal antibody intended to clear Aβ plaques in the brain. It targets pyroglutamyl(3)‐Aβ protein (3–42) to remove Aβ deposits and alter the disease course. This review explores the timeline of donanemab use from discovery to clinical use. The pharmacodynamics and pharmacokinetics of the drug are discussed along with typical and suboptimal preclinical and clinical trial results in terms of efficacy, safety, and tolerability. Thus, donanemab is more effective than donepezil and rivastigmine in removing plaques and improving cognition. At the same time, it is not devoid of safety concerns that are typical of the majority of amyloid‐targeted medicines. The control to end the treatment after plaque cleaning is a unique selling point for some patients, making it more attractive. The innovation and development of donanemab from research to clinical practice are a clear representation of the role of the field of translational medicine in the practical application of new knowledge in the treatment of AD.

show abstract

Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application

Jayaprakash,

Elumalai

2024

Chronic Diseases and Translational Medicine

View full text Add to dashboard Cite

show abstract

Ageing, proteostasis, and the gut: Insights into neurological health and disease

Akbar,

Toppo,

Nazir

2024

Ageing Research Reviews

View full text Add to dashboard Cite

Microglia Signatures: A Cause or Consequence of Microglia-Related Brain Disorders?

Mirarchi,

Albi,

Arcuri

2024

IJMS

View full text Add to dashboard Cite

Microglia signatures refer to distinct gene expression profiles or patterns of gene activity that are characteristic of microglia. Advances in gene expression profiling techniques, such as single-cell RNA sequencing, have allowed us to study microglia at a more detailed level and identify unique gene expression patterns that are associated, but not always, with different functional states of these cells. Microglial signatures depend on the developmental stage, brain region, and specific pathological conditions. By studying these signatures, it has been possible to gain insights into the underlying mechanisms of microglial activation and begin to develop targeted therapies to modulate microglia-mediated immune responses in the CNS. Historically, the first two signatures coincide with M1 pro-inflammatory and M2 anti-inflammatory phenotypes. The first one includes upregulation of genes such as CD86, TNF-α, IL-1β, and iNOS, while the second one may involve genes like CD206, Arg1, Chil3, and TGF-β. However, it has long been known that many and more specific phenotypes exist between M1 and M2, likely with corresponding signatures. Here, we discuss specific microglial signatures and their association, if any, with neurodegenerative pathologies and other brain disorders.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Comprehensive review on single-cell RNA sequencing: A new frontier in Alzheimer's disease research

Cited by 3 publications

References 117 publications

Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application

Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application

Ageing, proteostasis, and the gut: Insights into neurological health and disease

Microglia Signatures: A Cause or Consequence of Microglia-Related Brain Disorders?

Contact Info

Product

Resources

About